Oral Colostrum Macrophage-activating Factor for Serious Infection and Chronic Fatigue Syndrome: Three Case Reports.

Authors :: Inui T
Kubo K
Kuchiike D
Uto Y
Nishikata T
Sakamoto N
Mette M
Source :: Anticancer research [Anticancer Res] 2015 Aug; Vol. 35 (8), pp. 4545-9.
Publication Year :: 2015
Abstract: Background: Gc protein-derived macrophage-activating factor (GcMAF) immunotherapy has been steadily advancing over the last two decades. Oral colostrum macrophage-activating factor (MAF) produced from bovine colostrum has shown high macrophage phagocytic activity. GcMAF-based immunotherapy has a wide application for use in treating many diseases via macrophage activation or for use as supportive therapy.<br />Results: Three case studies demonstrate that oral colostrum MAF can be used for serious infection and chronic fatigue syndrome (CFS) without adverse effects.<br />Conclusion: We demonstrate that colostrum MAF shows promising clinical results in patients with infectious diseases and for symptoms of fatigue, which is common in many chronic diseases.<br /> (Copyright© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.)

Subjects :: Aged
Catastrophic Illness therapy
Fatigue Syndrome, Chronic etiology
Female
Fever drug therapy
Humans
Infections etiology
Macrophage Activation drug effects
Macrophages drug effects
Macrophages immunology
Middle Aged
Pregnancy
Colostrum immunology
Fatigue Syndrome, Chronic therapy
Immunotherapy methods
Infections therapy
Macrophage-Activating Factors therapeutic use
Neoplasms complications
Vitamin D-Binding Protein therapeutic use

Tools